Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.2.473

Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions  

Kumar, Yogesh (Diagnostic Radiology, Yale New Haven Health System at Bridgeport Hospital)
Sharma, Pranav (Department of Internal Medicine, Yale New Haven Health System at Bridgeport Hospital)
Bhatt, Neeraj (Diagnostic Radiology, Yale New Haven Health System at Bridgeport Hospital)
Hooda, Kusum (Diagnostic Radiology, Yale New Haven Health System at Bridgeport Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.2, 2016 , pp. 473-478 More about this Journal
Abstract
Hepatocellular cancer is a very common cause of cancer related deaths worldwide. Only 30-40% of patients present with early-stage disease open to curative treatments, such as resection or transplantation, while others can only undergo local therapies or palliative care. Various trans-arterial approaches have been used for treatment of hepatocellular carcinoma in patients who need a down-staging to liver transplantation, and who are not candidates for transplantation or radiofrequency ablation. Transarterial chemoembolization (TACE), transarterial embolization (TAE), drug-eluting beads, and radioembolization have been used for locoregional control, and have been shown to prolong the overall survival when compared with supportive care. In this review, we discuss patient selection, pre- and post-procedure imaging, techniques, safety, and clinical outcomes related to these therapies. Newer advances with future directions in various fields related to trans-arterial therapies are also discussed.
Keywords
Embolization; chemoembolization; hepatocellular carcinoma; chemotherapy; transarterial treatment;
Citations & Related Records
Times Cited By KSCI : 11  (Citation Analysis)
연도 인용수 순위
1 Lammer J, Malagari K, Vogl T, et al (2010). Prospective randomized study of doxorubicin eluting bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol, 33, 41-52   DOI
2 Lewandowski RJ, Kulik LM, Riaz A, et al (2009). A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant, 9, 1920-8.   DOI
3 Liapi E, Geschwind JF (2011). Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug eluting chemoembolization? Cardiovasc Intervent Radiol, 34, 37-49.   DOI
4 Llovet JM, Brú C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-38   DOI
5 Llovet JM, Real MI, Montana X, et al (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 359, 1734-9   DOI
6 Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90   DOI
7 Lo CM, Ngan H, Tso WK, et al (2002). Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatol, 35, 1164-71   DOI
8 Luo J, Guo RP, Lai E, et al (2011). Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol, 18, 413-20.   DOI
9 Ma TC, Shao HB, Xu Y, Xu K (2013). Three treatment methods via the hepatic artery for hepatocellular carcinoma - a retrospective study. Asian Pac J Cancer Prev, 14, 2491-4.   DOI
10 Marelli L, Stigliano R, Triantos C, et al (2007). Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol, 30, 6-25   DOI
11 Shi-Ying Wang, Wen-Hao Zhu, Sonya Vargulick, Sam Bill Lin, Zhi-Qiang Meng (2013). Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Asian Pac J Cancer Prev, 14, 5995-6000   DOI
12 Song SY, Chung JW, Lim HG, Park JH (2006). Nonhepatic arteries originating from the hepatic arteries: angiographic analysis in 250 patients. J Vasc Interv Radiol, 17, 461-9.   DOI
13 Wang ZJ, Wang MQ, Duan F, et al (2013). Clinical application of transcatheter arterial chemoembolization combined with synchronous C-arm cone beam CT guided radiofrequency ablation in treatment of large hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 1649-54.   DOI
14 Xie ZR1, Luo YL, Xiao FM, Liu Q, Ma Y (2015). Health related quality of life of patients with intermediate hepatocellular carcinoma after liver resection or transcatheter arterial chemoembolization. Asian Pac J Cancer Prev, 16, 4451-6.   DOI
15 Xu C, Lv PH, Huang XE, et al (2014). Safety and efficacy of sequential transcatheter arterial chemoembolization and portal vein embolization prior to major hepatectomy for patients with HCC. Asian Pac J Cancer Prev, 15, 703-6.   DOI
16 Yang J, Li C, Wen TF, et al (2014). Is hepatectomy for huge hepatocellular carcinoma (${\geq}10cm$ in diameter) safe and effective? A single-center experience. Asian Pac J Cancer Prev, 15, 7069-77.   DOI
17 Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: An Update. Hepatol, 53, 1020-2.   DOI
18 Zhang ZM, Zhang YM, Gao S, et al (2014). Treatment efficacy and prognostic factors for huge HCC based on Barcelona clinic liver cancer staging. Asian Pac J Cancer Prev, 15, 8823-8.   DOI
19 Atassi B, Bangash AK, Bahram A, et al (2008). Multimodality imaging following Y-90 radioembolization: a comprehensive review and pictorial essay. Radio Graphics, 28, 81-99.
20 Brown DB, Fundakowski CE, Lisker-Melman M, et al (2004). Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol, 15, 1209-18.   DOI
21 Covey AM, Brody LA, Maluccio MA, Getrajdman GI, Brown KT (2002). Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiol, 224, 542-7.   DOI
22 Can A, Dogan E, Bayoglu IV, et al (2014). Multicenter epidemiologic study on hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev, 15, 2923-7.   DOI
23 Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH (1994). Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma: a randomized controlled-study. Cancer, 74, 2449-2453.   DOI
24 Coldwell DM, Stokes KR, Yakes WF (1994).. Embolotherapy:agents, clinical applications, and techniques. Radio Graphics, 14, 623-43.
25 Deodhar A, Covey AM, Thornton R, et al (2010). Safety and efficacy of transcatheter arterial embolization with particles only in the treatment of hepatocellular carcinoma with portal vein thrombus. J Intervention, 3, 3-11
26 Georgiades CS, Hong K, D'Angelo M, Geschwind JF (2005). Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol, 16, 1653-9.   DOI
27 Hong K, Khwaja A, Liapi E, et al (2006). New intraarterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res, 12, 2563-7.   DOI
28 Iñarrairaegui M, Thurston KG, Bilbao JI, et al (2010). Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol, 21, 1205-12.   DOI
29 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
30 Kan Z, McCuskey PA, Wright KC, Wallace S (1994). Role of Kupffer cells in iodized oil embolization. Invest Radiol, 29, 990-3   DOI
31 Kennedy A, Nag S, Salem R, et al (2007). Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys, 68, 13-23   DOI
32 Khan G1, Hashim MJ (2015). Burden of virus-associated liver cancer in the Arab world, 1990-2010. Asian Pac J Cancer Prev, 16, 265-70.   DOI
33 Kim W, Clark TWI, Baum RA, Soulen MC (2001). Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol, 12, 965-8   DOI
34 Kloeckner R, Otto G, Biesterfeld S, et al (2010). MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol, 33, 532-40   DOI
35 Kong WD, Cao JM, Xu J, et al (2012). Impact of low versus conventional doses of chemotherapy during transcatheter arterial chemoembolization on serum fibrosis indicators and survival of liver cancer patients. Asian Pac J Cancer Prev, 13, 4757-61.   DOI
36 Kruskal JB, Hlatky L, Hahnfeldt P, et al (1993). In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol, 4, 741-7.   DOI
37 Kulik LM, Carr BI, Mulcahy MF, et al (2008). Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatol, 47, 71-81.